These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30871669)

  • 41. A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study.
    Edessa D; Likisa J
    PLoS One; 2015; 10(9):e0137492. PubMed ID: 26348618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).
    Nabity SA; Gunde LJ; Surie D; Shiraishi RW; Kirking HL; Maida A; Auld AF; Odo M; Jahn A; Nyirenda RK; Oeltmann JE
    PLoS One; 2021; 16(4):e0248115. PubMed ID: 33793577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determinants of alcohol use among people living with HIV initiating isoniazid preventive therapy in Ethiopia.
    Mukherjee TI; Hirsch-Moverman Y; Saito S; Gadisa T; Melaku Z; Howard AA
    Drug Alcohol Depend; 2019 Nov; 204():107465. PubMed ID: 31499239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality.
    Kyaw NTT; Kumar AMV; Kyaw KWY; Satyanarayana S; Magee MJ; Min AC; Moe J; Aung ZZ; Aung TK; Oo MM; Soe KT; Oo HN; Aung ST; Harries AD
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):322-330. PubMed ID: 30871663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tuberculosis preventive treatment uptake among people living with HIV during COVID-19 period in Addis Ababa, Ethiopia: a retrospective data review.
    Gebreegziabher SB; Ashuro AA; Kumssa TH; Teferi MY; Alemayue EA; Datiko DG; Yimer SA; Shagre MB
    BMC Infect Dis; 2024 May; 24(1):499. PubMed ID: 38760665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study.
    Ngugi SK; Muiruri P; Odero T; Gachuno O
    BMC Infect Dis; 2020 Apr; 20(1):294. PubMed ID: 32664847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania.
    Komba FF; Frumence G
    Pan Afr Med J; 2021; 38():197. PubMed ID: 33995803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.
    Jacobson KB; Niccolai L; Mtungwa N; Moll AP; Shenoi SV
    AIDS Care; 2017 Jul; 29(7):936-942. PubMed ID: 28147705
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues.
    Aït-Khaled N; Alarcon E; Bissell K; Boillot F; Caminero JA; Chiang CY; Clevenbergh P; Dlodlo R; Enarson DA; Enarson P; Ferroussier O; Fujiwara PI; Harries AD; Heldal E; Hinderaker SG; Kim SJ; Lienhardt C; Rieder HL; Rusen ID; Trébucq A; Van Deun A; Wilson N
    Int J Tuberc Lung Dis; 2009 Aug; 13(8):927-35. PubMed ID: 19723371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health system barriers to implementation of TB preventive strategies in South African primary care facilities.
    Van Ginderdeuren E; Bassett J; Hanrahan C; Mutunga L; Van Rie A
    PLoS One; 2019; 14(2):e0212035. PubMed ID: 30763378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implementing an isoniazid preventive therapy program for people living with HIV in Thailand.
    Danyuttapolchai J; Kittimunkong S; Nateniyom S; Painujit S; Klinbuayaem V; Maipanich N; Maokamnerd Y; Pevzner E; Whitehead S; Kanphukiew A; Monkongdee P; Martin M
    PLoS One; 2017; 12(9):e0184986. PubMed ID: 28949995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
    Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.
    Dhungana GP; Thekkur P; Chinnakali P; Bhatta U; Pandey B; Zhang WH
    BMJ Open; 2019 May; 9(5):e029058. PubMed ID: 31147370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.
    Tram KH; Mwangwa F; Chamie G; Atukunda M; Owaraganise A; Ayieko J; Jain V; Clark TD; Kwarisiima D; Petersen ML; Kamya MR; Charlebois ED; Havlir DV; Marquez C;
    AIDS Care; 2020 Jan; 32(1):119-127. PubMed ID: 31181961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol.
    Savinkina A; Muyindike W; Hahn JA; Emenyonu NI; Fatch R; Ngabirano C; Adong J; Jacobson KR; Linas BP
    Int J Tuberc Lung Dis; 2024 Jul; 28(7):335-342. PubMed ID: 38961548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
    Nyarubamba RF; Silumbwe A; Jacobs C; Maritim P; Mdoe P; Zulu JM
    BMC Infect Dis; 2022 Nov; 22(1):884. PubMed ID: 36434517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.
    Dowdy DW; Golub JE; Saraceni V; Moulton LH; Cavalcante SC; Cohn S; Pacheco AG; Chaisson RE; Durovni B
    J Acquir Immune Defic Syndr; 2014 Aug; 66(5):552-8. PubMed ID: 24853308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy.
    Sumner T; Houben RM; Rangaka MX; Maartens G; Boulle A; Wilkinson RJ; White RG
    AIDS; 2016 May; 30(8):1279-86. PubMed ID: 26950316
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study.
    Mindachew M; Deribew A; Memiah P; Biadgilign S
    Pan Afr Med J; 2014; 17():26. PubMed ID: 24932337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isoniazid preventive therapy use among adult people living with HIV in Zimbabwe.
    Takamiya M; Takarinda K; Balachandra S; Godfrey M; Radin E; Hakim A; Pearson ML; Choto R; Sandy C; Maphosa T; Rogers JH
    Int J STD AIDS; 2021 Oct; 32(11):1020-1027. PubMed ID: 33978529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.